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published economic evaluations of dialysis treatment modalities,
including hemodialysis (HD) and peritoneal dialysis (PD).
METHODS: We conducted a systematic literature review of
original research articles comparing PD and HD (or their
subtypes) in both PubMed and EMBASE for the years 1996 to
2006. Articles were included if they 1) came under the major
subject headings of “renal replacement therapy/economics,” or
“dialysis/economics,” or “renal dialysis/economics,” or “hemo-
dialysis units, hospital/economics,” or “kidney failure, chronic/
economics”, and 2) contained the term “peritoneal dialysis” and
either the term “hemodialysis” or “haemodialysis”. Pre-deﬁned
exclusion criteria were also applied. RESULTS: Twenty-ﬁve
articles were included in the formal literature review. The major-
ity of articles were cost evaluations, rather than full economic
evaluations of both costs and outcomes. The results show that, in
developed nations, HD is generally more expensive than PD to
the payer. Research is more limited in developing and emerging
countries. Due to inexpensive labor and high imported equip-
ment and solution costs, PD is perceived to be more expensive
than HD; however, the costs of dialysis differ by region and
additional research is needed in the developing world. CON-
CLUSION: HD is a more expensive dialysis modality in devel-
oped regions of the world. Research in the developing world is
too limited to draw deﬁnitive conclusions.
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OBJECTIVES: Vesicoureteral reﬂux (VUR) occurs in approxi-
mately 1% of infants and children and is associated with recur-
rent urinary tract infections (UTIs). Guidelines in the treatment
of VUR target reducing the number of UTIs in patients with
VUR. Treatment strategies include antibiotic prophylaxis, which
is the current ﬁrst-line treatment, as well as endoscopic injection
and surgery. The objective of this study is to examine the use of
endoscopic injection with dextranomer/hyaluronic acid (Dx/HA)
as a curative option and as an alternative to antibiotic prophy-
laxis as it is gaining in popularity in the treatment of VUR.
METHODS: The nationally representative PharMetrics Inte-
grated Medical and Pharmaceutical database was used to
conduct this retrospective analysis. Patients <11 years of age who
were continuously eligible with an International Classiﬁcation of
Diseases (ICD)-9-CM for VUR were identiﬁed. Resource utiliza-
tion and outcome measures were evaluated over a 6-month pre-
and 12-month post-index period. As randomization is not pos-
sible in a retrospective database analysis, patients were matched
3:1, antibiotic prophylaxis to Dx/HA, by age, gender, urinary
tract infections (UTIs) prior to index date, and diagnosing
physician specialty. The primary outcome assessed was UTIs.
RESULTS: Of the patients, 114 received a prescription for anti-
biotic prophylaxis and 38 underwent endoscopic injection with
Dx/HA between January 2000 and December 2004. The average
number of UTIs per year was 0.28 in the antibiotics cohort and
0.08 in the Dx/HA cohort, respectively. The incidence rate ratio
(IRR) of 4.826 (P = 0.029) revealed that the average number of
UTIs was 3.83 times greater for patients receiving antibiotic
prophylaxis compared with patients who underwent endoscopic
injection. CONCLUSION: Treatment with endoscopic injection
with Dx/HA resulted in signiﬁcantly fewer UTIs compared with
children receiving antibiotic prophylaxis, supporting a role for
Dx/HA as a ﬁrst-line treatment option for patients with VUR.
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OBJECTIVES: Around 1990 there was a social change in the
former socialist countries of Central and Eastern Europe. The
former dominance of the state has changed and many private
health care providers entered into the Hungarian health care
market. The aim of this study is to analyse how the market share
of private dialysis centres has changed. METHODS: Data were
derived from the nationwide database of the Hungarian National
Health Insurance Fund Administration (OEP), the only health
care ﬁnancing agency in Hungary. We analysed the period
between 1995 and 2005. Dialysis centres were classiﬁed into 3
major groups according to their ownership: private, central gov-
ernment (mainly at universities) and local authorities (mainly at
county level hospitals). All the Hungarian dialysis centres are
included into the study regardless of their ownership. RESULTS:
The market share of different type of providers in 1995 from
health insurance expenditures was the following: private provid-
ers 46.3%, central government 20.6% and local authorities
33.1%, which means that public ownership (20.6 + 33.1 = 53.7)
dominated the dialysis care. The market share of providers sig-
niﬁcantly changed for 2005: private providers 89.8%, central
government 5.3% and local authorities 4.9%. Between 1995–
2005 private providers doubled their market share, while dialysis
centres owned by the central government or local authorities lost
15.3 and 28.2 percent point respectively. CONCLUSION: The
ownership structure of dialysis centres dramatically changed in
Hungary after the social and political changes in the early 1990s.
The previous dominance of the state has disappeared, and most
of the dialysis care is provided by private for-proﬁt dialysis
centres.
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OBJECTIVES: To evaluate treatment outcomes, medical care
and resource consumption of patients with neurogenic detrusor
overactivity (NDO) before and after botulinum toxin A (BTA)
therapy in Germany. METHODS: In a multi-center, cross-
sectional, retrospective cohort study, information such as demo-
graphic characteristics, number of BTA therapies, urodynamic
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parameters, occurrence of urinary tract infection (UTI), number
of incontinence episodes, use of incontinence aids (e.g. absorbent
pads, urinary reservoirs) frequency and number of outpatient
consultations were collected by chart abstraction covering 12
months before and after ﬁrst BTA therapy. RESULTS: Seven
specialized hospitals enrolled 214 patients who received in total
418 BTA therapies between 2000 and 2006. Mean age was 38
years (SD 15), 68% were male. Seventy-seven percent suffered
from NDO due to spinal cord injury, 14% due to spina biﬁda and
5% due to multiple sclerosis. Within 12 months 51% of patients
received one BTA therapy, 41% two and 8% three BTA thera-
pies. On average, time interval between BTA therapies was 8.0
months (SD 4.2). Within 12 months before ﬁrst BTA therapy
63% of patients had incontinence episodes and 68% of patients
UTI, after BTA therapy 28% and 33%, respectively. Incontinence
aids were used by 58% of patients within 12 months before ﬁrst
BTA therapy and in 28% of patients after BTA therapy. In
patients, who had used incontinence aids, mean cost per day and
patient decreased from €2 (SD 2) to €1 (SD 2). Mean drug cost
per patient to treat UTI within 12 months decreased from €163
(SD 242) before treatment to €80 (SD 142) after the start of BTA
therapy. CONCLUSION: Presented data are the ﬁrst data
showing the clinical usefulness of botulinum toxin A under
naturalistic conditions in Germany. Moreover, occurrence of
incontinence and UTI was reduced resulting in lower cost
for incontinence aids and UTI medication.
URINARY/KIDNEY—Methods and Concepts
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OBJECTIVES: Overactive Bladder (OAB) is deﬁned as urgency,
with or without urge incontinence, usually with frequency and
nocturia. The prevalence of OAB in Korea is increasing more than
ever before. It is estimated at about 12.2% in adults aged over 18
years (men 10%, women 14.3%), and 14.9% in adults aged over
40 years (men 11.2%, women 18.4%). The study objective is to
evaluate the cost-effectiveness of Solifenacin compared with Tot-
erodine ER for patients with overactive bladder. METHODS: We
developed a decision-analytic model to estimate treatment pat-
terns, resource utilization, and costs for a six-month period with
a societal perspective. The clinical outcome (percentage reduction
in micturition frequency) and probabilities (Patient Perception of
Bladder Conditions, PPBC) for the 1st cycle were collected from
the literature, and the probabilities of each node for the 2nd cycle
were obtained from the literature and expert opinions through the
administration of a semi-Delphi survey where necessary. The cost
items were limited to drugs, monitoring, OAB induced comor-
bidities, physical therapies, surgery, and traveling to the hospital.
RESULTS: The expected cost of treating OAB patients with
Solifenacin (540,170 won) is 19,872 won less costly compared
with Extended-release Tolterodine (560,042 won). The Solifena-
cin arm also showed greater effectiveness than the Tolterodine
arm in percentage reduction in micturition frequency. When we
conducted a sensitivity analysis on success rate (PPBC) and
outcome (percentage reduction in micturition frequency), the
results showed robust. CONCLUSION: The results from this
study suggest that treatment with Solifenacin dominates
Extended-release Tolterodine in terms of lower cost and greater
effectiveness.
URINARY/KIDNEY—Patient Reported Outcomes
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OBJECTIVES: Icodextrin is a glucose polymer that has been
used to replace traditional glucose in peritoneal dialysis (PD)
solutions due to advantages such as improved ultra-ﬁltration
rates. The objective of this study was to estimate the impact of
icodextrin on quality of life (QoL) in patients with diabetes using
ordinary least square (OLS) regression models. METHODS:
Data were collected from a prospective, randomized, controlled,
open-label clinical trial where patients were assigned to one of
two arms. One arm (GLC) only received glucose-based solutions
(GBS). The other arm (ICO) also received GBS but for the long-
dwell they received icodextrin instead. QoL was measured using
the Spanish version of the KDQOL-SF-1.3. To be included in the
analysis, patients must have completed two QoL surveys at least
90 days apart. Twenty-three out of 29 GLC and 27 out of 30 ICO
patients qualiﬁed for the study. Two OLS regression models were
used to estimate the impact of certain variables on the change in
physical component (PCS) and mental component (MCS) scores.
The dependent variables were calculated as the difference
between the baseline and most recent PCS and MCS from the
QoL surveys. Independent variables included a dummy variable
for the study arm (1 = ICO, 0 = GLC), age, gender, and clinical
variables such as urine volume and blood pressure at baseline.
RESULTS: The regression equation for PCS had an adjusted R2
of 0.335. Patients whose PD therapy included icodextrin
reported signiﬁcantly (p < 0.01) greater improvement in their
PCS than those who only received GBS (5.3 points higher). The
MCS equation had an adjusted R2 of 0.232. There was no
signiﬁcant difference in MCS between the ICO and GBS group.
CONCLUSION: The use of icodextrin in patients with diabetes
on PD had better physical QoL outcomes than those who did not
use icodextrin.
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OBJECTIVES: Tolterodine ER (TER) was granted reimburse-
ment in neurogenic overactive bladder (OAB) patients by the
Belgian Health Authorities in 2003 under the condition that an
observational study be performed that conﬁrms clinically signiﬁ-
cant improvements in health-related quality of life (HRQoL) in
these patients. The results of the study are presented here.
METHODS: A multicentre prospective non-interventional study
was initiated in neurogenic OAB patients who discontinued
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